Pimavanserin, trade name Nuplazid, was approved by the FDA for the treatment of hallucinations and delusions in PD, per press release April 29.  Pimavanserin was granted an FDA breakthrough therapy designation, which is a program “designed to expedite the development and review of drugs intended to treat a serious condition and where preliminary clinical evidence indicates … Continue reading NEW DRUG: Pimavanserin Approved by the FDA